Skip to content
The BMJ
  • Latest
  • Authors
    • Columnists
    • Guest writers
    • Editors at large
    • A to Z
  • Topics
    • NHS
    • US healthcare
    • South Asia
    • China
    • Patient perspectives
    • More …

James Raftery’s NICE blogs

James Raftery: NICE’s proposed new QALY modifier for appraising highly specialised technologies

April 18, 2017

After a consultation on changes to its methods for appraising health technologies, the National Institute for Health and Care Excellence (NICE) has gone public with its way forward. As discussed previously, the consultation […]

More…

James Raftery's NICE blogs0 Comments

James Raftery: Changes to how NICE appraises drugs and other health technologies

December 2, 2016

The recent proposals by NICE and NHS England to change arrangements for evaluating and funding drugs and other health technologies not only tidy up the processes, but introduce some important new […]

More…

James Raftery's NICE blogs0 Comments

James Raftery on a short history of NICE

March 23, 2016

A terrible beauty: A short history of the National Institute for Health and Care Excellence by Nicholas Timmins, Michael Rawlins and John Appleby. Free download.   This story of NICE is […]

More…

James Raftery's NICE blogs0 Comments

James Raftery: Cancer drugs fund—consultation on bringing it under NICE

December 3, 2015

Conflict of interest: the proposals reviewed here are similar to those advocated in a 2014 BMJ editorial “Reforming the Cancer Drugs Fund” to which I was a co-author. I have […]

More…

James Raftery's NICE blogs0 Comments

James Raftery: Ever higher cancer drug prices—driven by US policies and genetic sequencing

July 1, 2015

The high prices charged by companies for cancer drugs has led to lots of speculation, but very little explanation. The most interesting attempt to explain these high prices has been […]

More…

James Raftery's NICE blogsCancer, cancer drugs, NICE0 Comments

James Raftery: Cancer drug prices and olaparib

June 4, 2015

NICE’s provisional rejection of Astra Zeneca’s olaparib (Lynparza) for a genetic subset (BRCA1/2 gene mutation) of ovarian cancers has several themes which have not been commented on. One is that […]

More…

James Raftery's NICE blogs1 Comment

James Raftery: NICE and value based pricing—is this the end?

October 22, 2014

Since Andrew Lansley announced in 2010 that the NHS would in future use “value based pricing” in its purchases of pharmaceuticals, civil servants and (more recently) the National Institute for […]

More…

James Raftery's NICE blogs0 Comments

James Raftery: NICE: “inconsistent,” “in large part arbitrary and opaque,” according to friends

August 29, 2014

A strong critique just published points to logical inconsistencies in NICE’s consideration of social values, specifically in how it handles quality adjusted life years (QALYs). Since these are key to […]

More…

James Raftery's NICE blogs1 Comment

James Raftery: Sofosbuvir for hepatitis C—moving to country specific prices

August 20, 2014

The National Institute for Health and Care Excellence (NICE) has provisionally approved sofosbuvir (brand name Sovaldi) for the treatment of hepatitis C, a decision that has surprised some commentators given its high […]

More…

James Raftery's NICE blogs4 Comments

James Raftery: Should the NHS use the new meningitis B vaccine?

March 28, 2014

The argument over whether the NHS should fund Bexsero, the new meningitis B vaccine from Novartis, raises a global issue about the price of the new vaccine, as well as […]

More…

James Raftery's NICE blogs0 Comments
  • 1
  • 2
  • 3
  • »Next page
  • 4

Comment and opinion from The BMJ's international community of readers, authors, and editors

Access bmj.com
The BMJ logo

Most Read

  • Elizabeth Loder: Gun violence in the US—the kids…
  • Patricia Cantley: We must remember how scary…
  • Irial Eno: The case of Albert Thompson is abhorrent,…

Categories

  • Author's perspective
  • BMJ Clinical Evidence
  • Brexit
  • China
  • Christmas appeal
  • Climate change
  • Columnists
    • Billy Boland
    • Daniel Sokol
    • David Kerr
    • David Lock
    • David Oliver
    • Desmond O'Neill
    • Douglas Noble
    • Edzard Ernst
    • Gerd Gigerenzer
    • Giles Maskell
    • Iain Chalmers
    • James Raftery's NICE blogs
    • Jeff Aronson's Words
    • Jim Murray
    • Julian Sheather
    • Kieran Walsh
    • Liz Wager
    • Marge Berer
    • Martin McKee
    • Martin McShane
    • Mary E Black
    • Matt Morgan
    • Muir Gray
    • Neal Maskrey
    • Nick Hopkinson
    • Paul Glasziou
    • Penny Campling
    • Peter Brindley
    • Pritpal S Tamber
    • Rachel Clarke
    • Richard Smith
    • Sandra Lako
    • Sian Griffiths
    • Siddhartha Yadav
    • Simon Chapman
    • Tara Lamont
    • Tiago Villanueva
    • Tracey Koehlmoos
    • William Cayley
  • Editors at large
    • Anita Jain
    • Anya de Iongh
    • Birte Twisselmann
    • David Payne
    • Domhnall MacAuley
    • Fiona Godlee
    • Georg Röggla
    • Juliet Dobson
    • Robin Baddeley
    • Sally Carter
    • Tessa Richards
  • Featured
  • From the archive
  • From the other side
  • Global health
  • Guest writers
  • Junior doctors
  • Literature and medicine
  • Medical ethics
  • Metaphor watch
  • MSF
  • NHS
  • Open data
  • Partnership in practice
  • Patient perspectives
  • Readers' editor
  • Richard Lehman's weekly review of medical journals
  • South Asia
  • Students
  • The BMJ today
  • The King's fund
  • Too much medicine
  • Uncategorized
  • US healthcare

Information for Authors

BMJ Opinion provides comment and opinion written by The BMJ's international community of readers, authors, and editors.

We welcome submissions for consideration. Your article should be clear, compelling, and appeal to our international readership of doctors and other health professionals. The best pieces make a single topical point. They are well argued with new insights.

For more information on how to submit, please see our instructions for authors.

  • Contact us
  • Website terms & conditions
  • Privacy policy
  • Revenue sources
  • Home
  • Top

© BMJ Publishing Group Limited 2023. All rights reserved.